These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 17392539)

  • 1. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women.
    Mathiesen ER; Kinsley B; Amiel SA; Heller S; McCance D; Duran S; Bellaire S; Raben A;
    Diabetes Care; 2007 Apr; 30(4):771-6. PubMed ID: 17392539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.
    Imbergamo MP; Amato MC; Sciortino G; Gambina M; Accidenti M; Criscimanna A; Giordano C; Galluzzo A
    Clin Ther; 2008 Aug; 30(8):1476-84. PubMed ID: 18803989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.
    Raskin P; Guthrie RA; Leiter L; Riis A; Jovanovic L
    Diabetes Care; 2000 May; 23(5):583-8. PubMed ID: 10834413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes.
    Danne T; Råstam J; Odendahl R; Näke A; Schimmel U; Szczepanski R; Moeller J; Deiss D
    Pediatr Diabetes; 2007 Oct; 8(5):278-85. PubMed ID: 17850471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the safety and effectiveness of insulin aspart with other bolus insulins in women with pre-existing Type 1 diabetes during pregnancy: A post hoc analysis of a prospective cohort study.
    Mathiesen ER; Alibegovic AC; Anil G; Dunne F; Halasa T; Ivanišević M; McCance DR; Nordsborg RB; Damm P;
    Diabet Med; 2024 Oct; 41(10):e15411. PubMed ID: 39115159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study.
    Tamás G; Marre M; Astorga R; Dedov I; Jacobsen J; Lindholm A;
    Diabetes Res Clin Pract; 2001 Nov; 54(2):105-14. PubMed ID: 11640994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Postprandial glycemic control using insulin aspart with NPH in inadequately controlled diabetics].
    Gao Y; Pan CY; Zou DJ; Xu ZR; Liu XM; Guo XH
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(28):1960-3. PubMed ID: 19950569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.
    Kølendorf K; Ross GP; Pavlic-Renar I; Perriello G; Philotheou A; Jendle J; Gall MA; Heller SR
    Diabet Med; 2006 Jul; 23(7):729-35. PubMed ID: 16842476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
    Hermansen K; Fontaine P; Kukolja KK; Peterkova V; Leth G; Gall MA
    Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E; Lang H; Roberts A
    Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
    Russell-Jones D; Bode BW; De Block C; Franek E; Heller SR; Mathieu C; Philis-Tsimikas A; Rose L; Woo VC; Østerskov AB; Graungaard T; Bergenstal RM
    Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus.
    Pettitt DJ; Ospina P; Howard C; Zisser H; Jovanovic L
    Diabet Med; 2007 Oct; 24(10):1129-35. PubMed ID: 17888133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus.
    Heller S; Bode B; Kozlovski P; Svendsen AL
    J Diabetes; 2013 Dec; 5(4):482-91. PubMed ID: 23586846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
    Hirsch IB; Bode B; Courreges JP; Dykiel P; Franek E; Hermansen K; King A; Mersebach H; Davies M
    Diabetes Care; 2012 Nov; 35(11):2174-81. PubMed ID: 22933438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
    Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T
    Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
    Vague P; Selam JL; Skeie S; De Leeuw I; Elte JW; Haahr H; Kristensen A; Draeger E
    Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoglycemia in type 1 diabetic pregnancy: role of preconception insulin aspart treatment in a randomized study.
    Heller S; Damm P; Mersebach H; Skjøth TV; Kaaja R; Hod M; Durán-García S; McCance D; Mathiesen ER
    Diabetes Care; 2010 Mar; 33(3):473-7. PubMed ID: 20007944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
    Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
    Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equal metabolic control but superior caregiver treatment satisfaction with insulin aspart in preschool children.
    Pańkowska E; Nazim J; Szalecki M; Urban M
    Diabetes Technol Ther; 2010 May; 12(5):413-8. PubMed ID: 20388052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.